T.D.E. Wedding has announced its commitment to meeting the growing demand for Chinese wedding planners in the diverse San Francisco Bay Area. As luxury Chinese weddings gain popularity, T.D.E. Wedding stands out, offering authentic and personalized experiences.
In areas like Millbrae, Palo Alto, Hillsborough, and Redwood City, T.D.E. Wedding is known for blending traditional Chinese customs with modern touches in their wedding celebrations. They hold a strong reputation for quality, providing a wide range of services like floral arrangements, photography, videography, and custom decor. These elements ensure that each wedding aligns with the couple’s unique vision.
The Chinese wedding planner San Francisco community is changing, focusing more on authenticity and luxury. Today, couples want personalized services that reflect who they are while honoring their cultural roots. T.D.E. Wedding is adapting to this shift with specialized services in planning and coordination, committed to creative execution.
Otis Fang, the founder of T.D.E. Wedding, shares the company’s mission: “Recognizing the different customs in Chinese weddings is crucial for us. We aim to create not just memorable celebrations, but ones that truly reflect the couple’s cultural background.”
T.D.E. Wedding’s comprehensive approach covers all aspects — from lighting and music to photo booths — ensuring everything matches the desired theme and personal style. This method resonates with clients in places like Millbrae, Palo Alto, and Menlo Park, where the desire for culturally rich weddings with personal touches is increasingly popular.
Chinese weddings have always been known for their vibrant colors, detailed designs, and rich traditions. Lately, there’s been a shift towards luxury, with couples choosing top-tier venues, gourmet catering, and a blend of Eastern and Western elements. T.D.E. Wedding excel in creating these special experiences by merging traditional customs like tea ceremonies and dragon dances with modern trends.
“Providing top-notch services that respect Chinese wedding traditions allows us to exceed expectations,” says Otis Fang. “We keep adapting to new trends, always mindful of the cultural importance of these events.”
By concentrating on authentic traditions and luxury aesthetics, T.D.E. Wedding is expanding its influence in the Bay Area. They tailor their offerings to not just meet but exceed the desires of sophisticated clients in Hillsborough, Portola Valley, and San Mateo, offering a seamless and elegant full-service experience.
As T.D.E. Wedding grows its presence in San Carlos and nearby areas, it is dedicated to crafting unique events that reflect each couple’s personal journey. Through their work, T.D.E. Wedding sets the standard for what it means to be a premier Chinese wedding planner in San Francisco. Each event showcases its commitment to creativity, quality, and cultural appreciation.
T.D.E. Wedding positions itself at the forefront of the luxury Chinese wedding trend in the Bay Area, blending tradition with modern elegance. Their extensive range of services and attention to personalized celebrations highlight their significant role in this thriving market. For more details on their services, one can visit their official website.
Revenue increased 67% y/y to $17.1M with Positive Adjusted EBITDA1 for Ninth Consecutive Quarter
Adjusted EBITDA1 increased 387% y/y to $2.9M or 17% of revenue
Net Profit for the quarter of $0.9M and EPS of $0.02
Reaffirms Fiscal 2025 Revenue Guidance Exceeding $60M, Driven by Strong Order Pipeline
TORONTO, ONTARIO / ACCESS Newswire / August 13, 2025 / Electrovaya Inc. (“Electrovaya” or the “Company”) (Nasdaq:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today reported its financial results for the third quarter of the fiscal year ending September 30, 2025 (“Q3 2025”). All dollar amounts are in U.S. dollars unless otherwise noted.
Financial Highlights:
Revenue for Q3 2025 was $17.1 million, compared to $10.3 million in Q3 2024, an increase of 67%. Year to date revenue was $43.3 million compared to $33.0 million in the prior year, an increase of 31%
Gross margin was 30.8% in Q3 2025. Battery system margins remained strong at 30.9% for the quarter.
Adjusted EBITDA1 was $2.9 million or 17% of revenue with growth of 387% year over year.
Net profit for the quarter was $0.9 million, compared to a net loss in the prior year of $0.3 million. Year to date net profit was $1.3 million compared to a net loss of $1.4 million in the prior year.
Earnings per share for the quarter was $0.02.
Key Operational and Strategic Highlights – Q3 2025
Continued Growth from OEM Partners and Leading End-Customers: Electrovaya maintained strong momentum with its key OEM partners and end customers in the material handling sector. In Q3, the Company secured more than $21 million in orders, bringing total orders to over $66 million in the nine months ending June 30th 2025. The Company continues to expand its robust sales pipeline, leveraging long-standing relationships with major OEMs and top-tier end customers.
Expanded Manufacturing Capacity and Output: To meet growing demand, Electrovaya implemented a second production shift at its Mississauga facility in mid-June and commenced assembly operations in Jamestown, NY in May. These initiatives will increase output for material handling battery systems and support the launch of new products for additional vertical markets
Infinity Technology Advancements: The Company continued to enhance its Infinity product line, achieving UL certification for more than 400 battery systems equipped with its latest high-capacity lithium-ion cells. New models feature improved ergonomics and AI-enabled capabilities, further strengthening Electrovaya’s competitive edge.
Development of New Products for Emerging Verticals: Electrovaya is leveraging its industry-leading Infinity technology to expand into a broader range of high-growth applications, including:
Robots and Autonomous Vehicles: The Company has introduced multiple battery system products for new robotic vehicle platforms across three distinct OEM customers. Applications range from material handling to surveillance systems. This initiative is part of a major product development program aimed at capturing share in the rapidly growing robotics market.
Airport Ground Equipment: Recently, Electrovaya launched products targeting the airport ground support segment and plans to showcase these solutions at the upcoming GSE Expo in Las Vegas this September.
Class 8 Trucks: As one of the largest potential markets for electrification, this segment represents a significant growth opportunity. Electrovaya has entered into a partnership with Janus Electric Holdings Limited, an Australian pioneer in heavy-vehicle electrification. The Company is developing custom high-voltage battery systems for a unique battery-swapping application in both U.S. and Australian markets.
Construction and Mining Equipment: Through its partnership with Sumitomo Corporation Power and Mobility, Electrovaya is pursuing opportunities with multiple Japan-based OEMs in these sectors.
Defense Applications: The Company continues to expand its collaboration with a global defense contractor on various electrification projects. With its superior safety and cycle life advantages, combined with upcoming U.S.-based lithium-ion battery manufacturing, Electrovaya is positioned to target the defense sector on a larger scale in the near term.
Jamestown Cell Manufacturing Update: The Company remains on track for start of cell manufacturing in mid calendar year 2026. Output from the Jamestown facility will remain eligible for 45X under the OBBB Act (2025).
Management Commentary:
“Our Q3 FY2025 results reflect the strong momentum we’ve built, with continued growth in both revenue and profitability, while advancing our industry-leading Infinity technology into a broader range of applications,” said Dr. Raj DasGupta, Electrovaya’s CEO. “The market is increasingly recognizing the exceptional advantages of our innovations. Electrovaya’s unique lithium-ion technology delivers the ideal solution for the most demanding equipment in the world. With the rise of AI and rapid expansion across sectors like e-commerce and robotics, we are well-positioned to provide superior battery solutions that power these high-growth industries.”
“FY Q3 2025 quarter was our ninth consecutive quarter of positive adjusted EBITDA1 and also our second consecutive quarterly net profit. Margins remained robust at above 30%, a trend that we expect to continue and strengthen over time.,” stated John Gibson, Electrovaya’s CFO. “Our second shift at our Mississauga operations, combined with the start up of assembly operations in Jamestown will continue to support increased manufacturing output as we complete our fiscal year and prepare for FY2026. We are confident in our ability to exceed $60 million in revenue for FY 2025 while advancing profitability and scaling operations.”
Positive Financial Outlook & Fiscal 2025 Guidance:
The Company anticipates strong growth into FY 2025 with estimated revenues to exceed $60 million driven by renewed demand from the Company’s largest end users of material handling batteries. This guidance considers its existing purchase orders, along with anticipated orders in its pipeline from key end users and customers. This guidance also takes into consideration a percentage of anticipated revenue that may be deferred to FY 2026 (please see Forward Looking Statements for further clarification).
Selected Financial Information for the quarters ended June 30, 2025 and 2024:
Results of Operations
(Expressed in thousands of U.S. dollars)
Adjusted EBITDA1
(Expressed in thousands of U.S. dollars)
1 Non-IFRS Measure: Adjusted EBITDA is defined as income/(loss) from operations, plus stock-based compensation costs and depreciation and amortization costs. Adjusted EBITDA does not have a standardized meaning under IFRS. Therefore it is unlikely to be comparable to similar measures presented by other issuers. Management believes that certain investors and analysts use adjusted EBITDA to measure the performance of the business and is an accepted measure of financial performance in our industry. It is not a measure of financial performance under IFRS, and may not be defined and calculated in the same manner by other companies and should not be considered in isolation or as an alternative to IFRS measures. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is income (loss) from operations.
Summary Financial Position
(Expressed in thousands of U.S. dollars)
The Company’s complete Financial Statements and Management Discussion and Analysis for the quarter and nine months ended June 30, 2025 are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov, as well as on the Company’s website at www.electrovaya.com.
To help ensure that the conference begins in a timely manner, please dial in 10 minutes prior to the start of the call.
For those unable to participate in the conference call, a replay will be available for two weeks beginning on August 13, 2025 through August 27, 2025. To access the replay, the dial-in number is 877-481-4010 and 919-882-2331. The replay passcode is 52770.
Investor and Media Contact:
Jason Roy VP, Corporate Development and Investor Relations Electrovaya Inc. jroy@electrovaya.com / 905-855-4618
About Electrovaya Inc.
Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries without compromising energy and power. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation, and other specialized applications. Electrovaya has two operating sites in Canada and a 52-acre site with a 135,000 square foot manufacturing facility in Jamestown New York state for its planned gigafactory. To learn more about how Electrovaya is powering mobility and energy storage, please explore www.electrovaya.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements that relate to, among other things, revenue growth and revenue guidance of approximately $60 million in FY 2025, other financial projections, including projected sales, cost of sales, gross margin, working capital, cash flow, and overheads anticipated in FY 2025, the expected timing of deliveries of pre-production battery modules in Japan, anticipated cash needs and the Company’s requirements for additional financing, purchase orders, mass production schedules, funding from EXIM and the ability to satisfy the conditions to drawing on any facility entered into with EXIM,, use of proceeds of the EXIM facility,, ability to deliver to customer requirements. Forward-looking statements can generally, but not always, be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors and assumptions are applied in making forward looking statements, and actual results may differ materially from those expressed or implied in such statements. In making the forward-looking statements included in this news release, the Company has made various material assumptions, including but not limited to assumptions with respect to the Company’s customers deploying its products in accordance with communicated intentions, the Company’s customers completing new distribution centres in accordance with communicated expectations, intentions and plans, anticipated new orders in FY 2025 based on customers’ historical patterns and additional demand communicated to the Company and its partners, but not yet provided as a purchase order together with the Company’s current firm purchase order backlog totaling approximately $80 million, a discount of approximately 25% used in the revenue modeling applied to the overall expected order pipeline to account for potential delays in customer orders, expected decreases in input and material costs combined with stable selling prices in FY 2025, delivery of ordered products on a basis consistent with past deliveries, and that the Company’s customer counterparties will meet their production and demand growth targets, ]the Company’s ability to successfully execute its plans and intentions, including with respect to the entry into new business segments and servicing existing customers, the availability to obtain financing on reasonable commercial terms, including any EXIM facility. Factors that could cause actual results to differ materially from expectations include but are not limited to customers not placing orders roughly in accordance with historical ordering patterns and communicated intentions, macroeconomic effects on the Company and its business, and on the lithium battery industry generally, not being able to obtain financing on reasonable commercial terms or at all, including not being able to satisfy any condition of drawdowns under any EXIM facility if entered into, that the Company’s products will not perform as expected, supply and demand fundamentals for lithium-ion batteries, the risk of interest rate increases, persistent inflation in the United States and Canada and other macroeconomic challenges, the political, economic, and regulatory and business stability of, or otherwise affecting, the jurisdictions in which the Company operates, including new tariff regimes. There have been indications from the United States government of potential tariffs on Canada, Mexico and other countries, which if enacted would have a material impact on the Company. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s Annual Information Form for the year ended September 30, 2024 under “Risk Factors”, and in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Qualitative And Quantitative Disclosures about Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities and filed or furnished with the SEC. The Company does not undertake any obligation to update publicly or to revise any of the forward looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Revenue guidance for FY2025 described herein constitutes future‐oriented financial information and financial outlooks (collectively, “FOFI“), and generally, is, without limitation, based on the assumptions and subject to the risks set out above under “Forward‐Looking Statements”. Although management believes such assumptions to be reasonable, a number of such assumptions are beyond the Company’s control and there can be no assurance that the assumptions made in preparing the FOFI will prove accurate. FOFI is provided for the purpose of providing information about management’s current expectations and plans relating to the Company’s future performance, and may not be appropriate for other purposes.
The FOFI does not purport to present the Company’s financial condition in accordance with IFRS, and it is expected that there may be differences between audited results and preliminary results, and the differences may be material. The inclusion of the FOFI in this news release disclosure should not be regarded as an indication that the Company considers the FOFI to be a reliable prediction of future events, and the FOFI should not be relied upon as such.
BETHLEHEM, PA / ACCESS Newswire / August 13, 2025 / Buzzi Unicem USA, a prominent U.S. cement manufacturer and subsidiary of Buzzi S.p.A is partnering with UptimeAI, a leading provider of AI-powered operational excellence solutions, to deploy an artificial intelligence-based program aimed at transforming asset reliability and operational performance at its Festus, MO plant.
The collaboration began with a pilot deployment of AI Expert, UptimeAI’s flagship platform, to gain deeper insights into operational parameters and their correlation, asset performance, prediction of equipment failures and reduction of maintenance costs. Powered by advanced AI and machine learning algorithms trained on more than 1,000 failure modes, AI Expert is expected to enable predictive diagnostics and informed decision-making. Its two primary core modules, “AI Expert: Generative AI” and “AI Expert: Reliability and Process,” aim to streamline operational parameters, root cause analysis, support continuous improvement and enhance knowledge management across plant operations.
The platform emulates the reasoning of experienced engineers by combining historical data, real-time operating conditions, and institutional knowledge to detect issues early to recommend targeted corrective actions.
“Unlike generic deviation detectors, our platform acts as a virtual process and reliability engineer,” Jagadish Gattu, founder and chief executive officer of UptimeAI, said. “AI Expert is purpose-built for complex industrial operations like we see at Buzzi Unicem USA to learn from plant-specific data with a comprehensive view approach mimicking the reasoning of seasoned engineers, to bridge the gap between human expertise and scalable AI.”
“Partnering with UptimeAI reflects our commitment to continuously improving reliability and performance,” Antonio Buzzi, president and chief executive officer of Buzzi Unicem USA, said. “This initiative supports our core value of continuous evolution. We pursue excellence, embrace innovation and face change with courage to achieve lasting, sustainable results. We expect UptimeAI’s platform to provide deep operational insight, to equip our teams with smart decisions and, most importantly, to support and share critical plant operational knowledge across our organization.”
This partnership reflects the companies’ shared commitment to driving innovation and advancing sustainable operations. As the cement industry faces increasing pressure to reduce unplanned downtime and lower its carbon footprint, AI-powered solutions are rapidly emerging as a strategic lever for competitiveness and long-term resilience.
About Buzzi Unicem USA
Buzzi Unicem USA Inc., part of the global Buzzi Unicem Group, is a leading cement manufacturer headquartered in Bethlehem, Pa. The company operates eight full-cycle cement plants and 36 cement terminals across the U.S., delivering high-quality materials and advancing innovation in construction. Learn more at: www.buzziunicemusa.com
About UptimeAI
UptimeAI is a San Francisco-based provider of AI-based operational excellence solutions for heavy industries. Its proprietary “AI Expert” platform enables organizations to improve asset reliability, efficiency, and sustainability by replicating the knowledge of top engineers at scale. UptimeAI is trusted by Global industry leaders in cement, power, oil and gas, and chemicals. More at: www.uptimeai.com | Contact: info@uptimeai.com
RENO, NV / ACCESS Newswire / August 13, 2025 / Pershing Resources Company, Inc., (OTC PINK:PSGR) is pleased to announce that Pamela Laudenslager, (Pam), has joined the Company’s Advisory Board, effective immediately. In her role as a member of the Advisory Board, Ms. Laudenslager will be advising the Company regarding marketing, financing and, social media presence.
Ms. Laudenslager is the Managing Partner of Hemisphere Two Group LLC, a New York-based consulting/advisory group focusing on business planning and strategy as well as project funding while cultivating strategic partnerships. She is also a partner in Future Food Frontiers Pty., an innovative Australian aggrotech business that is currently being rolled out globally.
Ms. Laudenslager’s is an experienced marketing executive who’s career has spanned senior executive positions in marketing, sales and communications for several Fortune 500 companies involved in Broadway, entertainment, publishing, media, and cosmetics. Pam began her career after graduating college by serving on the White House Advance Team under President Gerald Ford. Upon completion of government service in the Ford administration, she became a Director for Avon Products in NYC. After distinguishing herself at Avon, she was tapped to become Senior Vice President with Estee Lauder. Pam has also held a position as the publisher for “The American Benefactor,” a magazine dedicated to philanthropy. As an entrepreneur, Pam co-founded Three Roads Media Partners, LLC, and was CEO of Center Stage Capital, Inc., a Broadway production company, which garnered her two Tony Awards.
Pam is deeply committed to philanthropic and civic leadership. She serves as President of her New York City co‑op, on the Board of Directors of Land of Friends Care Group and serves on the Board of Directors of the Neurology Trauma Research Foundation. Her philanthropic and leadership roles include board and trustee positions at BideaWee, Animal Rescue, NYC, Green Mountain College, New York Blood Center, and Sheltering Arms Children’s Services (NY). She holds an Associate of Arts degree from Green Mountain College and a Bachelor of Arts from Cedar Crest College.
Joel Adams, Chief Operating Officer of Pershing Resources, stated, “We are very pleased to welcome Pam to our team. Her experience and judgment as an entrepreneur, in fundraising, as well as, marketing and corporate development of early-stage companies will be invaluable as we move forward.”
To receive information on Pershing Resources, sign up for email news alerts at: http://ir.pershingpm.com/.
Forward-Looking Statements
The information contained in this press release, as well as the information on the Company’s website, is provided solely for the reader’s general knowledge. Such information is not intended to be a comprehensive review of all matters pertaining to the Company. Certain statements included herein, and, on the Company’s, website, constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, these forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the Company’s management. When used in this press release and on the Company’s website, words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “plan,” “possibility,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, and/or achievements of the Company or of the mining industry, in general, to be materially different from future results, performance and/or achievements expressed or implied by those forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties related to fluctuations in gold, silver, copper and other precious and base metals commodity prices; uncertainties relating to interpretation of drill results and the geology of the Company’s properties; uncertainty of estimates of capital and operating costs; the need for cooperation of government agencies in the development of the Company’s mineral projects; the need to obtain additional financing to develop the Company’s mineral projects, the possibility of delay in development programs or in construction projects; uncertainty of meeting anticipated program milestones for the Company’s mineral projects; the risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and its variants; the risks associated with the continuing conflict between the Ukraine and Russia; and other risks and uncertainties affecting the Company’s business operations and financial condition.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. The Company has no obligation, and expressly disclaims any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information or future events.
CONTACT:
Pershing Resources Company, Inc. 200 South Virginia Street, 8th Floor Reno, NV 89501 Phone: 775-398-3124 Email: info.psgr@pershingpm.com
Visit Highlights Mississippi’s Role in Defense Innovation and Economic Growth
TUPELO, MS / ACCESS Newswire / August 13, 2025 / General Atomics Electromagnetic Systems (GA-EMS) welcomed Mississippi Gov. Tate Reeves to its Manufacturing Center of Excellence in Tupelo, Miss on Tuesday, August 12, where he toured the facility and met with company leaders to discuss Mississippi’s expanding role in national defense and advanced manufacturing.
Reeves emphasized the importance of high-tech job creation and public-private partnerships in driving economic growth. GA-EMS briefed him on its manufacturing capabilities and weapons systems that complement the Golden Dome for America initiative including hypersonics, directed energy, space-based missile tracking and warning payloads and Bullseye™, the company’s long range precision-guided missile that will be produced in Mississippi. The Governor was also briefed on GA-EMS’ investments and initiatives to support the expansion of the maritime and submarine industrial bases and its nuclear power solutions for future Mississippi data centers.
“General Atomics is helping build the future of American defense right here in Mississippi,” Reeves said. “Their work reflects the strength of our workforce and the success of our pro-growth policies. Mississippi is breaking economic development records and bringing in billions in new private sector investment – and it’s thanks to great companies like General Atomics.”
GA-EMS operates more than 750,000 square feet of manufacturing space in Tupelo and maintains additional facilities in Iuka, Miss., with strategic access to world ports via the Tennessee-Tombigbee Waterway to support future shipbuilding and logistics expansion.
“This facility represents our long-term commitment to building resilient, world-class manufacturing capability in Mississippi,” said Scott Forney, president of GA-EMS. “We’re investing in infrastructure and workforce development to deliver advanced technologies at scale for critical national defense priorities and to facilitate military readiness.”
About General Atomics Electromagnetic Systems
General Atomics Electromagnetic Systems (GA-EMS) develops innovative technologies to create breakthrough solutions supporting operational environments from undersea to space. From electromagnetic, power generation and energy storage systems and space systems and satellites, to hypersonic, missile defense, and laser weapon systems, GA-EMS offers an expanding portfolio of capabilities for defense, government, and national security customers. GA-EMS also provides commercial products and services targeting hazardous waste remediation, oil and gas, and nuclear energy industries.
ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the FriskaAi platform. Under the agreement, data from Dexcom CGMs will be integrated with Friska Ai, the company’s groundbreaking AI-powered healthcare platform supporting physicians and patients with actionable personalized care management programs.
FriskaAi is a physician-directed health and wellness platform that supports the management of diabetes and other chronic diseases by helping providers take an evidence-based approach to preventive care. The EHR-agnostic FriskaAi platform leverages advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health journey in partnership with their clinical team.
“Impacting more than 38 million Americans, diabetes has emerged as a major public health problem, and its effective management has become a foundational element of preventive medicine,” says Shaji Nair, CEO of FriskaAi. “Dexcom’s pioneering CGMs are vital tools not only for diabetes management but also for informing broader care decisions. FriskaAi is excited about the potential this integration with Dexcom presents to the physicians relying on our platform for chronic disease management and the patients seeking greater control over their health and wellness.”
Dexcom CGMs use a small, wearable sensor to continuously measure and send glucose levels wirelessly to a smart device or receiver in real-time, without the need for fingerpricks. Dexcom CGMs also offer a suite of customizable alerts that can warn of high or low glucose levels and send predictive alerts to help users spend more time in range.
The FriskaAi mobile app securely integrates with Dexcom CGMs and other smart devices, as well as health apps, for analysis by the powerful HIPAA-compliant FriskaAi platform. That data, along with other clinical data and studies, is continuously monitored by sophisticated AI-powered algorithms that alert the patient when action is recommended and generate actionable reports for use by the clinician at the point of care to inform care decisions.
Aggregated health data is also analyzed within the FriskaAI platform to help physicians identify trends and risks within their patient populations, enabling more proactive and preventive care strategies.
About FriskaAi
FriskaAi is a powerful AI-enabled EHR-agnostic platform that helps physicians and other providers take an evidence-based approach to preventive care. The physician-initiated platform leverages advanced AI- and mobile technology to provide patients with personalized health insights and recommendations, empowering them to take control of their health journey in partnership with their clinical team. This aggregated health data, including information from patients’ glucometers, other smart devices, and health apps, is continuously analyzed by advanced evidence-based algorithms that alert the patient when action is needed and provide clinicians with actionable reports to inform care decisions. FriskaAi also supports population health strategies by analyzing aggregated health data to identify trends and risks within a defined patient population. For more information, visit www.friska.ai.
Media Contact: Michele Nachum NPC Creative Services michele@npccs.com
BROOKLYN, NY / ACCESS Newswire / August 13, 2025 / IEH Corporation (OTC:IEHC) yesterday filed with the Securities and Exchange Commission (SEC) its quarterly report on Form 10-Q for the 1st fiscal quarter ended June 30, 2025.
Highlights include:
11% Decrease in Revenue as compared to first quarter of Fiscal Year 2025
$755,306 loss in Operating Income
Cash 43% higher than first quarter of Fiscal Year 2025
Backlog increase of 25% since beginning of Fiscal Year 2026
Over $2.5 million in orders supporting missile defense programs booked in recent weeks
For the quarter ended June 30, 2025, IEH had revenues of $6,308,155 as compared to $7,104,977 for the quarter ended June 30, 2024 reflecting an 11% decrease; an operating loss of $755,306 for 1st quarter fiscal year 2026 as compared to an operating gain of $332,979 for 1st quarter fiscal year 2025; a net loss of $654,618 for 1st quarter fiscal year 2026 as compared to a net gain of $392,787 for 1st quarter fiscal year 2025; and a basic loss per share of $.27 for 1st quarter fiscal year 2026 as compared to a basic gain per share of $.17 for 1st quarter fiscal year 2025.
Dave Offerman, President and CEO of IEH Corporation commented, “As forecasted in prior communications, while our long-term trajectory continues to trend upwards, our results from one quarter to the next may be uneven. This is reflected in our first quarter, as revenue was lower than the last few quarters due primarily to customer schedule delays, along with the still slow recovery of the commercial aircraft sector.
However, the long-term projections, especially in our largest sector, defense, remain strong. Indeed, we recently booked over $2.5 million in orders in support of various missile defense programs, including PATRIOT, AMRAAM, LTMADS and others. Our sales pipeline indicates more orders are on the horizon. Our commercial space launch business continues to grow, and we continue to eagerly anticipate a return to pre-COVID levels of business in the commercial aerospace sector. Initiatives to grow our product lines and markets served via organic and inorganic growth continue, and we look forward to sharing more good news in the coming quarters.
On behalf of the management team and staff of IEH, we again wish to express our sincere gratitude for the support of our valued shareholders.”
About IEH Corporation
For over 80 years and 4 generations of family-run management, IEH Corporation has designed, developed, and manufactured printed circuit board (PCB) connectors, custom interconnects and contacts for high performance applications. With its signature Hyperboloid technology, IEH supplies the most durable, reliable connectors for the most demanding environments. The Company markets primarily to companies in defense, aerospace, medical, space and industrial applications, in the United States, Canada, Europe, Southeast and Central Asia and the Mideast. The Company was founded in 1941 and is headquartered in Brooklyn, New York.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this press release, and in related comments by the Company’s management, include “forward-looking statements.” All statements, other than statements of historical facts, including, without limitation, statements or expectations regarding our financial condition, statements or expectations regarding our revenues, cash and backlog, expectations regarding future cash requirements, revenue and revenue recovery, including for fiscal year 2026 and beyond, projected timelines for making our SEC filings or successfully preventing our registration from suspension or revocation and expectations regarding our efforts and ability to resolve our inventory accounting issues are forward-looking statements. These statements often include words such as “believe,” “expect,” “estimate,” “plan,” “will,” “may,” “would,” “should,” “could,” or similar expressions, although not all forward-looking statements contain such identifying words. These statements are based on certain assumptions that the Company has made on its current expectations and projections about future events. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and you should not place undue reliance on any forward-looking statements. The Company’s actual performance or results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, as they will depend on many factors about which we are unsure, including many factors beyond our control. Among other items, such factors could include: any claims, investigations or proceedings arising as a result of our past due periodic reports, including changes in the proceedings related to the SEC’s Order Instituting Administrative Proceedings and Notice of Hearing pursuant to Section 12(j) of the Securities and Exchange Act of 1934, as amended; our ability to remediate our inventory accounting issue; our ability to reduce costs or increase revenue; changes in the macroeconomic environment or in the finances of our customers; changes in accounting principles, or their application or interpretation, and our ability to make accurate estimates and the assumptions underlying the estimates; our ability to attract and retain key employees and key resources; and other risk factors discussed from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on June 12, 2025, and in subsequent reports filed with or furnished to the SEC. Additional information concerning these and other factors can be found in our filings with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this press release as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in our filings with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.
XCF Global and OpenSponsorship partner to provide sports, entertainment, and music industries with carbon-neutral air travel opportunities
Initiative drives awareness around reducing aviation emissions by offering a practical carbon offset solution
Partnership empowers athletes, entertainers, and musicians to leverage their platforms to promote positive societal change
HOUSTON, TEXAS / ACCESS Newswire / August 13, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Synthetic Aviation Fuel (“SAF”) today announces a strategic partnership with OpenSponsorship Corp. (“OpenSponsorship”), a New York-based marketing agency specializing in sponsorships for sports and entertainment industries to drive awareness for carbon-neutral air travel. This campaign creates unique opportunities for sports teams, actors and actresses, and musicians to participate in carbon-neutral travel activities, raising awareness around the decarbonization of air travel.
As part of the partnership, XCF will offer a comprehensive carbon offset solution for sports and entertainment travel, ensuring that flights to games,tournaments, concerts, and other events are fully carbon neutral. Such sponsorships aim to demonstrate a practical and impactful approach to sustainability, contributing to the global movement toward reducing emissions from the aviation industry.
Mihir Dange, CEO and Board Chair of XCF Global commented:
“We are thrilled to partner with OpenSponsorship and bring carbon-neutral travel opportunities to sports, entertainment, and music industries. This partnership enables high-profile individuals and organizations to meaningfully engage with their audiences by showcasing their leadership in sustainability and driving awareness of the need to decarbonize the aviation industry. Together, we’re turning the spotlight on the urgent need to decarbonize the aviation industry and providing a clear path for others to follow.”
OpenSponsorship is revolutionizing the sponsorship landscape by simplifying the connection between brands and talent in the sports, entertainment, and music industries. Their platform provides brands of all industries with streamlined access to the benefits of sports and entertainment sponsorships, empowering them to engage with talent and athletes through mutually beneficial partnerships.
OpenSponsorship Founder and CEO, Ishveen Jolly said:
“We’re excited to work with XCF to bring carbon-neutral travel to the forefront of sports and entertainment sponsorships. Athletes, musicians, and actors hold immense influence, and their global followings make them powerful advocates for change. This partnership empowers them to lead by example, using their platforms to inspire fans and effect positive societal change.”
XCF Global, Inc. is a pioneering synthetic aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality. The company is actively building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~149.3 million; 20% free float (as of August 13, 2025).
This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses resulting from potential inflationary pressures and rising interest rates, including manufacturing and operating expenses and interest expenses; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing in the future and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (11) costs related to the Business Combination and the New Rise acquisitions; (12) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (13) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (14) changes in applicable laws or regulations; (15) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (16) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (17) the availability of tax credits and other federal, state or local government support; (18) risks relating to XCF Global’s and New Rise’s key intellectual property rights; (19) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (20) the effects of increased costs associated with operating as a public company; and (21) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global makes with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.
RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted and allowed across key global markets, will enable the Company’s long-term strategy of pursuing broader indications for the technology, beginning with its lead program as a critical medical countermeasure for military and first responders against high-potency opioids.
This announcement follows recent positive feedback from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) pathway for TH-104. The FDA confirmed that a 505(b)(2) NDA submission for the prevention of respiratory and/or central nervous system distress is a viable path, and no additional clinical trials seem to be required for this specific indication for use in military personnel and/or first responders who may be exposed to weaponized high-potency opioids, such as fentanyl or its analogues. This positive feedback, combined with the appointment of counter-terrorism expert James Liddy to the Board of Directors, accelerates the Company’s efforts to position TH-104 as a national security solution.
The recent granting and allowance of patents in Japan, Mexico, Australia, and the United States further strengthen the Company’s intellectual property position, providing protection for TH-104 out to at least 2040 in key markets. While the initial focus is on military and first responders, these patents are foundational for addressing other significant medical needs to combat pruritus, a debilitating form of itch associated with certain chronic liver and kidney diseases.
TH-104 is a buccal film formulation of nalmefene, an opioid antagonist with a significantly longer half-life compared to existing options of autoinjectors and other formulations containing the active ingredient of products such as Narcan®. This extended duration may provide sustained protection, which is crucial for personnel operating in high-risk environments where repeated dosing may not be feasible.
“The recent patent grants are important for our TH-104 platform,” said Sireesh Appajosyula, CEO of Tharimmune. “This is a dual achievement which validates our innovative drug delivery technology and secures the long-term potential of TH-104 to address multiple high-impact indications. While we are prioritizing its role as a life-saving medical countermeasure for our military and first responders, this patent portfolio provides a runway to develop our lead candidate for other debilitating conditions where there is a significant unmet medical need.”
The newly granted and allowed patents specifically cover a novel method and device for transmucosal administration of nalmefene via a single-layer, self-supporting, mucoadhesive film with distinct domains for optimized drug delivery and pH balance.
The granted and allowed patents include:
United States (US) Application No. 17/285,971 (Allowed)
Japan (JP) Patent No. 7603583 (Granted)
Mexico (MX) Patent No. 422769 (Granted)
Australia (AU) Patent Application No. 2019361980 (Allowed)
Tharimmune is dedicated to advancing TH-104 to provide a potentially effective and patient-friendly treatment as an option for those in need, beginning with its critical role in national security.
About Tharimmune, Inc.
Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune’s future Phase 2 trial, Tharimmune’s strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. Subsequent events and developments may cause the Company’s views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies
Ended the quarter with $4.8 million of cash to fund operations
FRAMINGHAM, MA / ACCESS Newswire / August 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the second quarter 2025.
Recent Highlights
Expanded its collaboration with The Scripps Research Institute (“TSRI”) to advance the development of the Company’s development program evaluating the combination of systemic DNase I and CAR T-cell therapies;
Announced advancements from its collaboration partner, PeriNess Ltd. (“PeriNess”) including:
Entered into a Clinical Study Agreement to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma;
Commenced patient dosing in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer at Bnei Zion Medical Center; and
Continued pursuit of other strategic collaborations to advance the Company’s technology.
“We continue to set a strong foundation that we believe positions us for success as we advance our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy across various oncology indications where there remains significant unmet need. We continue to work with our partners and believe the data and information will be invaluable as we look to realize the full potential of our DNase platform technology. Looking ahead, we remain focused on building momentum across all fronts and driving development toward an IND and Phase 1 clinical trial,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapies, and CAR-T therapy in hematological and solid tumor and metastatic cancer models have been completed. Building on proof-of-concept success, the program has now advanced to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial.
Additionally, as previously announced in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
Summary of Financial Results for Second Quarter 2025
Net loss for the quarter ended June 30, 2025 was approximately $0.7 million. Research & development expenses for the three months ended June 30, 2025 decreased by approximately $277,000, or 29.7%, to approximately $0.7 million from $0.9 million in the comparable quarter in 2024. General and administrative expenses for the three months ended June 30, 2025 decreased by approximately $472,000, or 41.8%, to approximately $0.7 million from approximately $1.1 million in the comparable quarter in 2024. These decreases were primarily due to certain severance and benefits expensed in connection with separation agreements entered into during the second quarter of 2024 with the Company’s former Chief Executive Officer and Chief Scientific Officer.
The Company ended the quarter with approximately $4.8 million in cash.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company’s DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: (a) advancing our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors and our focus on building momentum and driving development toward an IND and Phase I clinical trial, (b) setting a strong foundation that we believe positions us for success as we advance DNase I in combination with various types of therapy and (c) working with our partners and our belief regarding the data and information as we look to realize the full potential of DNase. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 xbio@jtcir.com
